1. Cao T, Jiang N, Liao H, Shuai X, Su J, Zheng Q. The flt3-itd mutation and the expression of its downstream signaling intermediates stat5 and pim-1 are positively correlated with cxcr4 expression in patients with acute myeloid leukemia. Sci Rep. 2019;9(1):1–10.
2. Pratz KW, Levis MJ. Bench to bedside targeting of FLT3 in acute leukemia. Current Drug Targets. 2010;11(7):781–9.
3. Small D. FLT3 mutations: biology and treatment. ASH Edu Prog Book. 2006;2006(1):178–84.
4. Thiede C, Steudel C, Mohr B, Schaich M, Schäkel U, Platzbecker U, Wermke M, Bornhäuser M, Ritter M, Neubauer A, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood J Am Soc Hematol. 2002;99(12):4326–35.
5. Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA, Walker H, Wheatley K, Bowen DT, Burnett AK, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood J Am Soc Hematol. 2001;98(6):1752–9.